Hutchison China MediTech
Hong Kong, China

Hutchison China MediTech, a Hong Kong-based biopharmaceutical company, is on track to become a global leader in the discovery, development, and commercialisation of innovative, highly selective oral tyrosine kinase inhibitor therapies for oncology and immunological indications.

www.chi-med.com

Investment Perspective

Data at AACR from two key non-small cell lung cancer (NSCLC) trials has shown that savolitinib has encouraging anti-tumour activity and an acceptable safety profile both as monotherapy in exon 14m/del NSCLC, and in combination with osimertinib in MET+ EGFR-TKI refractory NSCLC. These presentations increase our confidence in Hutchison China MediTech (Chi-Med) and partner AstraZeneca’s ability to launch savolitinib, as the first available selective c-Met inhibitor, in its respective NSCLC settings in 2021 (China: MET exon 14m/del) and 2022 (Global: in combination with osimertinib), subject to positive trial read outs and subsequent approvals. We upgrade our valuation to $35.57/ADS or £54.72/share.

Market information

SymbolExchangesCurrency
HCMNASDAQ/AIM LondonUSD
Last PriceMarket Cap
52 Week Low52 Week High

Research

Proposed listing in Hong Kong and global offering
Lighthouse | 15 Apr 2019
AACR 2019: Savolitinib in the spotlight in NSCLC
Update | 09 Apr 2019
Bringing Global Innovation and China Oncology into focus
Update | 21 Mar 2019

Recent News

Application to list in Hong Kong and proposed global offering
15 Apr 2019
Initiation of Surufatinib China Phase IIb/III in Unresectable or Metastatic BTC
29 Mar 2019
Oral Presentations on Savolitinib Lung Cancer Programs at AACR
28 Mar 2019
2018 Annual Report and Notice of AGM
21 Mar 2019